Form 4: 4D Molecular Therapeutics Director Shawn Tomasello Granted 22,500 Stock Options

Shawn Tomasello, a Director at 4D Molecular Therapeutics, Inc., was granted 22,500 stock options with an exercise price of $4.15 as part of the company's non-employee director compensation program.

Summary

• Shawn Tomasello, a Director of 4D Molecular Therapeutics, Inc. (FDMT), was granted 22,500 stock options on June 17, 2025.
• The exercise price for these options is $4.15 per share.
• These options were automatically granted under the company's non-employee director compensation program.
• The options will vest in stages: 1/3 of the total shares will vest on June 17, 2026, with the remaining shares vesting in equal monthly installments thereafter.
• Full vesting is expected by June 17, 2028, provided the reporting person continues their service to the Issuer.
• Additionally, the stock options will vest in full immediately upon the consummation of a Change in Control, as defined in the 2020 Incentive Award Plan.
• The options have an expiration date of June 16, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine stock option grant to a director, which is a neutral to slightly positive event as it aligns director incentives with shareholder interests. It does not contain information that would significantly alter the company's financial outlook or operational status.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the options gain value if the stock price increases above the exercise price.
• It represents a standard component of non-employee director compensation, indicating a structured approach to rewarding board service.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the stock options is subject to the future performance of 4D Molecular Therapeutics, Inc.'s stock price. If the stock price does not exceed the exercise price of $4.15, the options may expire worthless.
• The vesting of the options is contingent upon Shawn Tomasello's continued service to the company.

Future Outlook

The stock options are designed to incentivize long-term commitment from the director, with vesting contingent on continued service through June 17, 2028, and potential full vesting upon a Change in Control.

Industry Context

The granting of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to align director interests with shareholder value and to attract and retain qualified board members.

Comparison to Industry Standards

• The grant of 22,500 stock options with a multi-year vesting schedule and an exercise price tied to the grant date's market value is consistent with standard non-employee director compensation practices in the U.S. public company landscape, particularly within the biotech sector where equity compensation is prevalent. Specific comparable companies or projects are not mentioned in the document, but this structure is typical for incentivizing long-term board service.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially encouraging decisions that enhance shareholder value. It also represents a dilution potential if options are exercised, though this is typically factored into compensation plans.

Next Steps

• Continued service of Shawn Tomasello to 4D Molecular Therapeutics, Inc.
• Vesting of 1/3 of the stock options on June 17, 2026.
• Subsequent monthly vesting installments until full vesting on June 17, 2028.
• Potential full vesting upon a Change in Control event.

Key Dates

Keywords

4D Molecular Therapeutics, FDMT, SEC Form 4, stock options, director compensation, equity grant, Shawn Tomasello, insider transaction, vesting schedule, non-employee director